Introduction
The G glycoprotein from vesicular stomatitis virus (VSV-G) has been used extensively for pseudotyping retroviral and lentiviral vectors.
1,2 VSV-G is advantageous for genetransfer protocols because of its broad species and tissue tropism, and its ability to confer physical stability and high infectivity to vector particles. 3 However, the high fusogenicity of VSV-G causes rapid syncytia formation and cell death, making it difficult to generate stable cell lines expressing the protein. 4 A number of groups have generated stable packaging and producer cell lines using VSV-G, but in all cases a repressible or inducible promoter regulates the expression of VSV-G. [4] [5] [6] While regulated expression avoids the problem of VSV-G cytotoxicity, it makes stable production of viral vectors more complicated and cell line generation more timeconsuming.
The broad tissue tropism of VSV-G has its disadvantages as well. For certain in vivo gene-therapy applications, it may be important to restrict the transfer and expression of the gene to specific cell types. Following systemic administration, the VSV-G pseudotyped vectors transduce target cells of interest, but can also transduce other cell types that would have undesirable effects in gene-therapy protocols. For example, antigen-presenting cells (APCs) could cause deleterious immune responses if they are transduced inadvertently. Unfortunately, VSV-G-pseudotyped lentivectors can efficiently transduce APCs from mice and humans, and can elicit immune responses against the transgene product, thus potentially negating the therapeutic effects of the protein expression. [7] [8] [9] [10] Systemic administration of viral vectors also exposes the particles to possible inactivation by serum complement. 11 Complement inactivation of vectors is dependent on the species derivation of the cell line used to produce the vectors, as well as the identity of the envelope glycoprotein used for pseudotyping. 12, 13 VSV-G pseudotypes, regardless of producer cell type, will be inactivated by human serum complement, while vectors pseudotyped with other envelope glycoproteins such as the MLV amphotropic envelope (Ampho) or RD114 are resistant to inactivation. 14, 15 Owing to the many disadvantages of VSV-G, there is considerable interest in examining alternative envelope glycoproteins that might have more suitable properties for use with retroviral or lentiviral vectors in gene-transfer applications. Of particular advantage would be identification of an envelope that could confer high titer in vivo, low cytotoxicity to enable producer cell line development, resistance to complement and reduced ability to transduce APCs.
We became interested in testing the major envelope protein of baculovirus, gp64, for its ability to pseudotype lentiviral vectors based on the infectivity characteristics of baculoviral vectors. Baculovirus (Autographa californica nuclear polyhedrosis virus, AcNPV) is an enveloped insect virus that is being developed as a vector for gene therapy. 16 Early studies showed that baculovirus vectors could efficiently transduce human hepatocyte cell lines and explanted human liver tissue. 17, 18 Subsequently, it was demonstrated that baculovirus vectors could enter a broader variety of human cell types. [19] [20] [21] We set out to determine whether gp64 could be used to pseudotype other viral vectors and confer high infectivity in cells of hepatic origin, which are primary targets for many genetherapy applications.
Very recently, a report was published that described the use of baculovirus gp64 for pseudotyping HIV-1 vectors. 22 These studies demonstrated that gp64-pseudotyped vectors had high titer on several cell lines, and could be concentrated 100-fold by ultracentrifugation. Importantly, it was also shown that gp64 could be constitutively expressed in a stable cell line with no cytotoxic effects. 22 The authors showed that this stable cell line could be used to package lentiviral vectors and might enable large-scale production of vectors without regulated expression of the envelope. 22 To further explore the utility of gp64 pseudotyping, we carried out extensive analysis of gp64 for cell and species tropism in vitro, using 24 different target cell lines, and determined the sensitivity of gp64-pseudotyped vectors to human complement inactivation. We also scaled up production of gp64-pseudotyped vectors, and determined the binding and elution properties of these vectors during particle purification by anion-exchange chromatography. Finally, we carried out two distinct experiments to analyze the in vivo transduction efficiency of gp64-pseudotyped vectors. Here we show that gp64 confers efficient gene transfer in vivo, and that gp64-pseudotyped vectors are human complement sensitive and have tropism restricted against hematopoietic cells including human dendritic cells (DCs). 22 
Results
Baculovirus gp64 envelope protein confers high infectivity to third-generation HIV-1 lentiviral vectors Kumar et al 22 recently reported that the baculovirus gp64 envelope protein could pseudotype viral vectors based on HIV-1. While our vector of choice (also derived from HIV-1) is slightly different from that used in their published studies, we were also interested in using gp64 for pseudotyping, based on the ability of baculovirus vectors to infect human cell types. Our thirdgeneration vector differs in that there are three additional HIV genes deleted (tat, nef and vpu) and the vector is produced through expression of Rev protein in trans. 23 To confirm that gp64 could also pseudotype this more advanced HIV vector, pseudotyped lentiviral vector particles were prepared and tested for their ability to transduce three human cell lines. Several independent batches of third-generation HIV-1 vector particles carrying the gene-encoding green fluorescent protein (GFP) were prepared by transient transfection, and pseudotyped with the VSV-G envelope glycoprotein or baculovirus gp64. The unconcentrated viral supernatants from the transfected cells were tested for infectious titer using 293T, HuH7 human hepatoma and HeLa cells as targets (Figure 1a) . We found that the gp64-pseudotyped vector was infectious in all the three cell lines, with average titers ranging from 8.1 Â 10 4 to 1.2 Â 10 6 transducing units (TU)/ml. The titers of the VSV-G-pseudotyped vectors ranged from 7.8 Â 10 5 to 4 Â 10 6 TU/ml on the same cell types. The gp64-pseudotyped vector titers were reduced 25-fold on 293T cells compared to VSV-G, but were only three-fold lower than VSV-G on HuH7 cells. The relative titer was the highest on HeLa cells, with gp64 titer (9.3 Â 10 5 TU/ml) slightly higher than the VSV-G titer (7.8 Â 10 5 TU/ml). In addition, we found that the Figure 1a) .
The titer differences between pseudotypes and preparations could be due to differences in the level of vector output in the transient transfections. To account for possible variations in total particle production, the p24
Gag protein levels were quantitated by ELISA and the infectious titer values were normalized to ng of p24
Gag to give the infectivity (TU/ng p24 Gag ), which reflects the ratio of infectious particles to total particles (Figure 1b) . The p24
Gag levels in the preparations of gp64-pseudotyped particles were generally lower than those for VSV-G-pseudotyped particles, a phenomenon that seemed to be specific to transient expression of gp64 protein. On comparing these normalized values for the two vectors, we found that gp64 vector infectivity was eight-fold lower than VSV-G on 293T cells, but there was no significant difference between their infectivities on HuH7 and HeLa target cells.
It is possible that transduction using gp64-pseudotyped vector particles resulted in GFP-positive cells due to carryover of GFP protein from the transfected producer cells (pseudotransduction) instead of integration of the transduced GFP vector genome. 24, 25 However, it was previously reported that integrated transgene DNA could be detected in target cells transduced with gp64-pseudotyped vectors, indicating that gp64 could mediate true gene transfer. 22 To eliminate the possibility of pseudotransduction in our experiments, we passaged gp64 vector-transduced cells and examined transgene expression after 2 weeks in culture. Cells that are pseudotransduced should show a decrease over time in percent GFP-positive cells and in GFP fluorescence intensity, due to degradation of the GFP protein. Instead, both VSV-G and gp64-vector-transduced cells maintained the same percentage of GFP-positive cells over this time period, and in both cases the GFP fluorescence intensity increased over time (data not shown).
Comparison of gp64 and VSV-G infectivities on various cell lines in vitro
To fully exploit their utility in gene-therapy applications, it is important to assess the tissue and species tropisms of different envelope glycoproteins. As a step toward analyzing the tropism of gp64-pseudotyped lentiviral vectors, we determined the infectivity of these pseudotypes on a variety of cell lines in vitro.
Preparations of VSV-G and gp64-pseudotyped lentiviral vectors carrying a CMV-GFP transgene cassette were generated by transient transfection, and concentrated 100-fold by ultracentrifugation. As previously reported, the gp64-pseudotyped vectors can be ultracentrifuged with no substantial loss of titer or p24
Gag and no change in the vector infectivities (data not shown). 22 The concentrated vector preps were analyzed for p24 Gag concentration and then tested for end-point titers on a variety of cell lines. Infectivity values were calculated by dividing the titer value by the p24 Gag concentration (Figure 2 ). The infectivity values for VSV-G and gp64 using 293T, HuH7 and HeLa target cells were slightly different from those determined in separate experiments (see Figure 1 ). These small disparities are probably due to slight differences in the vector preparations and the typical variation of the titer assay, and not due to concentration, since the average infectivities of unconcentrated and concentrated preps were similar. The gp64 infectivity was equivalent or better than VSV-G infectivity on a number of cell lines (Figure 2a ), including Vero, HuH7, U-118 MG, A549, HUAEC, Cf2Th and XC cells. The relative infectivity for gp64 pseudotypes was slightly reduced (less than 10-fold lower than VSV-G) on 293T, Hep3B, G-361, PC-3, HeLa, Ovcar-3 and NIH/3T3 cells. However, there were several human cell lines such as HepG2, Te671 and HT-1080, where the gp64 pseudotype infectivity was more than 10-fold lower than VSV-G. Surprisingly, the gp64 pseudotypes exhibited low infectivity in cells of hematopoietic origin (Figure 2b ). Initially, we found no detectable transduced cells when gp64-pseudotyped vector was used to infect MOLT-4, C8166 and CEM-TART cells (all human T-lymphocyte cell lines). The same vector preps were used for titrations on all of the cell lines in Figure 2 , indicating that the lack of transduction on hematopoietic cells was not due to lack of active vector particles. Subsequently, we looked at other hematopoietic cell types and found no detectable infectivity for gp64 vector on KG-1 human myeloblasts or on Raji and SC-1 human B lymphocytes, and extremely low infectivity on the K-562 human erythroleukemia cells and FO mouse B lymphocyte cells.
Finally, we analyzed the gp64 infectivity on DCs because published reports indicated that VSV-Gmediated transduction of APCs such as DCs may contribute to immune responses against the transgene product or vector. 9, 26 For this analysis, primary normal human dendritic cells (NHDCs) were obtained and transduced with the VSV-G and gp64 vectors. Again, there was no detectable transduction activity of the gp64 vector using these target cells, whereas the VSV-Gpseudotyped vectors transduced the NHDC at 100 times the limit of detection.
Overall, gp64-pseudotyped vectors were inefficient at transducing cells of hematopoietic origin, including human T lymphocytes and primary human DCs. This profile demonstrates that gp64 has a more restricted set of cell types that can efficiently transduce compared to VSV-G. On the other hand, gp64 infectivity levels were similar to those of VSV-G on many cell lines, suggesting that gp64 pseudotyping might be a useful alternative for transduction of many target tissues.
gp64-pseudotyped lentiviral vectors efficiently transduce mouse cells in vivo
It is reported that gp64-pseudotyped lentiviral vectors were able to efficiently transduce a number of cell lines in vitro. 22 However, it was not known if the gp64-pseudotyped vectors could transduce cells in vivo and confer long-term gene expression. To determine whether gp64 could confer significant infectivity in vivo, we looked for evidence of gene transfer in mice after injection of pseudotyped lentiviral vectors. An initial mouse experiment was designed using human Factor IX as the reporter transgene to facilitate detection of transduction and transgene expression. Factor IX is easily quantified and can be detected in the blood following secretion from many tissues. 27 Since the in vivo tissue tropism for gp64 was unknown, we used the constitutive CMV promoter to drive Factor IX expression and to avoid problems of tissue-specific expression.
To generate vectors for injection into mice, vector production was scaled up from 10 cm dishes into cell factories and large-scale transient transfections were performed in the 10-stacks. Three lentiviral vector preparations carrying the CMV-human Factor IX transgene cassette and pseudotyped with VSV-G, gp64 or the MLV amphotropic envelope (Ampho) were generated in this manner. The vector particles from all the three preparations were then purified by anion exchange chromatography. Both the gp64 and Ampho-pseudotyped vector particles bound to and eluted from the DEAE column under the same conditions as the VSV-G pseudotypes, and 100% of the input vector was recovered using this process (data not shown). The final vector preparations were characterized by testing for p24
Gag concentration, and were confirmed to transduce 293T cells in vitro and express human Factor IX protein (data not shown). For each of the vectors, approximately 10 mg of p24
Gag (or PBS as a negative control) was injected into Swiss Nude mice (three mice per vector pseudotype) via a hepatic portal vein cannula. The doses in 293T TU for each vector were as follows: VSV-G mice received 5.8 Â 10 7 TU, the gp64 mice received 1.8 Â 10 7 TU and the Ampho mice were injected with 1.7 Â 10 7 TU. Serum was collected from the mice at various time points after injection and analyzed for human Factor IX protein levels by ELISA (Figure 3 ). Mice injected with PBS or the Ampho-pseudotyped lentiviral vector did not express any detectable Factor IX protein at any time point. The mice injected with VSV-G-pseudotyped vector expressed detectable human Factor IX protein beginning at Day 7 after injection, and continuing at a stable level of 12-17 ng/ml for greater than 9 weeks. Mice injected with the gp64-pseudotyped vector expressed a stable level of 5-10 ng/ml human Factor IX for more than 9 weeks. Mice injected with the gp64-pseudotyped vector expressed only slightly less Factor IX than the VSV-G vector-injected mice, despite having received approximately three-fold lower TU. Figure 3 Expression of human Factor IX in Swiss Nude mice following injection with pseudotyped lentiviral vectors. Preparations of lentiviral vectors carrying a CMV-driven human Factor IX transgene and pseudotyped with the VSV-G, gp64 or MLV amphotropic envelope glycoproteins were produced by large-scale transient transfection followed by purification and concentration. These preparations were tested for p24
Gag concentration and infectivity was confirmed using 293T cells in vitro. A volume of 100 ml of each vector preparation or 100 ml of PBS as a negative control was injected into each of three NIH Swiss Nude mice. The final doses of TU determined using 293T target cells were: 5.8 Â 10
7 TU for VSV-G, 1.8 Â 10
7 TU for gp64 and 1.7 Â 10 7 TU for the Ampho vector. Blood was collected from the injected mice at time points after injection, as indicated on the X-axis. The concentration of human Factor IX in the mouse serum was determined by ELISA. Data points indicate the average human Factor IX concentration in the three mice with the corresponding standard deviations. VSV-G (squares with dashed line), gp64 (triangles with solid line), Ampho (X's with dashed line) and PBS control (diamonds with solid line).
gp64-pseudotyped lentiviral vectors in vivo
The expression of human Factor IX in mice after injection with pseudotyped lentiviral vectors showed that the VSV-G and gp64 envelopes could confer efficient transfer of a gene into mouse cells in vivo. To determine whether liver cells in the mice were being transduced, we injected mice with pseudotyped vectors carrying a CMV-GFP transfer vector and examined liver sections for GFP expression. A total of 12 Swiss Nude mice (three mice per group) were injected via a hepatic portal vein cannula with PBS or with lentiviral vectors carrying the CMV-GFP gene cassette pseudotyped with VSV-G (Figure 4 ). The patterns of GFP expression were consistent throughout each liver and between the three mice in each group (data not shown). In both the mice injected with VSV-G-pseudotyped vector and mice injected with gp64 vector, approximately 3-5% of liver cells were positive for GFP. The majority of the positive cells in both experimental groups were nonparenchymal cells (possibly Kupffer or sinusoidal cells), while a few were hepatocytes (Figure 4b) . The gp64-vector-injected mice also showed a slightly greater number of GFPpositive hepatocytes compared to VSV-G (Figures 4b, c) . Approximately the same number of liver cells was positive in the VSV-G and gp64 mice, despite the injection of less than half as many 293T-TU in the gp64 vector dose. Finally, very few GFP-positive cells were observed in the livers of the Ampho vector-treated mice, though virtually all were hepatocytes (Figure 4d ). In the Factor IX and GFP experiments, VSV-G and gp64 showed similar and significant expression, with notably lower or undetectable expression in the Ampho vector-treated mice.
gp64-pseudotyped vector particles are sensitive to inactivation by human serum complement Lentiviral vectors produced from human cells pseudotyped with VSV-G but not Ampho envelope are sensitive to inactivation by human serum complement.
14 To determine whether gp64-pseudotyped lentiviral particles are resistant or sensitive to complement, we tested the effects of human, rat and mouse serum on the infectivity of gp64-pseudotyped vector preparations. VSV-G-and gp64-pseudotyped lentiviral vectors carrying the GFP transgene were produced by transient transfection in 293T cells and concentrated 100-fold by ultracentrifugation. Titers were determined using 293T cells as targets and the vector preps were normalized to a concentration of 10 6 GFP TU/ml. The vector suspensions were diluted 1:5 into normal or heat-inactivated serum or into medium as a no-serum control. After incubation at 371C for 1 h, the suspensions were diluted and used to infect 293T target cells to determine end-point titers. The titer of the no-serum control samples were calculated and set as 100% recovery of titer for the reaction. The titer of samples exposed to serum is reported as a fraction of the 100% control sample. VSV-G pseudotypes were sensitive to inactivation, with complement-active serum causing 30-100-fold reduction in titer (Figure 5a, left) . The gp64-pseudotyped lentiviral vector was also sensitive to inactivation by the human sera. In all, 20-50-fold reductions in titer for gp64 pseudotypes were observed in the serum from the same donors (Figure 5b, right) . The human serum samples were tested for hemolytic complement activity (CH 50 ), and all were found to be in the normal range (data not shown).
The inactivation of gp64-pseudotyped particles by serum from mice and rats was also evaluated. It has been reported that baculovirus vectors produced in insect cells are sensitive to substantial inactivation in vitro by human, rat and guinea-pig serum, and that the vectors have extremely poor infectivity in vivo in mice and rats due to complement inactivation. [28] [29] [30] By testing gp64-pseudotyped lentiviral vectors, whether the complement sensitivity of baculovirus vectors in rodent serum is due to recognition of the specific envelope glycoprotein or the insect-derived lipid envelope could be evaluated. In this study, the gp64-pseudotyped lentiviral vectors were not inactivated by serum from C57BL/6 mice or Nude rats (Figure 5b ). Neither the pooled serum from C57BL/6 mice (two mice sera per pool) nor the serum from a single donor rat caused more than a four-fold reduction in titer, unlike the more severe inactivation observed in human serum (Figure 5a ). VSV-G-and Ampho-pseudotyped vectors were also resistant to inactivation by both the mouse and rat sera (data not shown). Thus, like VSV-G, the gp64 envelope glycoprotein makes lentiviral vectors sensitive to inactivation by human serum, but not by mouse or rat serum. Figure 4 Expression of GFP in mouse livers following injection with pseudotyped lentiviral vectors. Preparations of lentiviral vectors carrying a CMV-GFP transgene cassette and pseudotyped with the VSV-G, gp64 or MLV amphotropic envelope glycoproteins were produced by large-scale transient transfection, followed by purification and concentration. These preparations were tested for p24
Gag concentration and infectivity was determined using 293T target cells in vitro. A volume of 100 ml of each vector preparation or 100 ml of PBS as a negative control was injected into each of three NIH Swiss Nude mice via portal vein cannula. The final doses of TU determined using 293T target cells were: 3. 
Discussion
In this study, we report the additional characterization of lentiviral vectors pseudotyped with baculovirus gp64 as an alternative to VSV-G. Kumar et al 22 reported recently that gp64 could pseudotype an early-generation HIV-1 vector and confer titers greater than 10 6 TU/ml. The studies reported here confirmed the ability of gp64 to pseudotype HIV vectors almost as efficiently as the VSV-G envelope protein, and also extended the previous work into in vivo studies using third-generation lentiviral vectors lacking the HIV tat gene as well as all four HIV accessory genes. The infectivity of the gp64-pseudotyped vectors on 293T cells was several-fold lower than that of VSV-G pseudotypes, while it was very near or higher than the VSV-G infectivity on HuH7 and HeLa cells. The absolute titers and relative infectivities of VSV-G versus gp64 pseudotypes reported here differ slightly from the results of Kumar et al. 22 The slight discrepancies may be due to the differences in the viral vectors and target cells or variation in the method of titer determination. While we found that the absolute titers (TU/ml) of gp64-pseudotyped lentiviral vectors were slightly lower than for VSV-G vectors, this was generally due to lower particle production (lower p24
Gag concentration) in the transiently produced gp64 vector preparations. This phenomenon could be overcome by producing vector particles in cells that were stably expressing gp64. We also found that gp64 could be used to pseudotype an MLV-based oncoretroviral vector and could confer titers in the same range as the pseudotyped lentiviral vectors (data not shown). This result extended the published report that gp64 can also pseudotype vectors based on HIV-2, showing that gp64 pseudotyping may be feasible with any member of the retrovirus family. 22 Analysis of the in vitro tropism of gp64 suggested that gp64 pseudotyping might be advantageous for applications where tissues such as the liver, lung, skin, glia, endothelium or thymus are targets for transduction, because gp64 infectivity was high on cell lines derived from these tissues. In addition, reasonable infectivity (greater than 10 3 TU/ng p24) for gp64-pseudotyped vectors was observed in monkey (Vero), dog (Cf2Th), rat (XC) and mouse cells (NIH/3T3), indicating that gp64 could transduce cell types in several species that would be useful preclinical animal models. Kumar et al 22 examined six target cell lines and observed similar titers for both gp64 and VSV-G pseudotypes. 22 Extensive examination of 24 target cell types indicated that gp64 infectivity varies more widely than that of VSV-G. The disparities in infectivity may be due to differences in the ability of the vector particles to bind to the target cells, implicating possible variations in the abundance of gp64 receptors on the different cell types. Different reports have suggested that phospholipid molecules including phophatidylinositol and phosphatidic acid as well as proteins are possible gp64 receptors. [31] [32] [33] [34] Alternatively, there may be differences in the membrane composition that affect the fusion of the viral membrane with the target cell membrane after binding has occurred. Indeed, membrane lipid composition has been shown to affect fusion mediated by gp64, probably as a result of differences in the shape of the fusion intermediate structures in the envelope. 31 Unfortunately, because the variations in membrane lipid composition and protein levels between these different cells has not been explored, it is unclear whether the pattern and range of gp64 pseudotype infectivity in the different cell types correlate with modulations in receptor attachment or other membrane fusion factors.
Interestingly, gp64-pseudotyped lentiviral vectors were extremely inefficient at transducing human T-lymphocyte cell lines and other hematopoietic cell types. This restricted transduction of hematopoietic cell lines was also reported in published studies using baculovirus vectors, where K-562 and MOLT-4 cells as well as several other B-and T-lymphocyte cell lines were poorly infected. 17, 20, 21 This restricted tropism of gp64 may preclude the use of this envelope protein for genetherapy applications targeting the blood or immune system. However, because the gp64-pseudotyped vectors could not transduce NHDC to any detectable level, the selective tropism of gp64 might prove to be beneficial for some cases. Lentiviral vectors pseudotyped with VSV-G can transduce human and mouse DCs with high efficiency and induce humoral immune responses against transgene products. 7,9,26 Also, VSV-G itself has been demonstrated to elicit antibody responses.
14, 35 The inability of gp64 pseudotypes to transduce DCs suggests that there could be a reduction in immune responses against the vector components or against the transgene products in vivo when gp64-pseudotyped vectors are used. gp64-pseudotyped lentiviral vectors in vivo CA Schauber et al After determining that the gp64-pseudotyped lentiviral vectors showed significant infectivity on a number of cell lines in vitro, we set out to confirm that the envelope could also confer infectivity in vivo. We demonstrated that gp64-pseudotyped lentiviral vectors efficiently transfer the human Factor IX gene or the GFP gene to mouse cells following portal vein injection, contrary to several published studies that baculovirus vectors are not infectious if injected into the vasculature of mice. 18, 32 This indicates that the baculovirus infection is blocked at the postentry step and not at the receptor-binding or entry stage. The selectivity of the Ampho-pseudotyped lentiviral vectors for transduction of hepatocytes was interesting and novel. Previous studies showed that the Ampho receptor Pit2 should be highly expressed in liver tissue, but the exact cell types of expression were not delineated. 36 Published reports have shown that retroviral vectors carrying the amphotropic envelope can transduce hepatocytes, but in most circumstances liver proliferation has been induced to overcome the cell cycle requirement of these vectors; so the transduction patterns are not entirely dependent on the envelope. 37, 38 Thus, this study is the first reported use of Amphopseudotyped lentiviral vectors in vivo, and demonstrates the transduction of mouse hepatocytes in the absence of any liver proliferation.
A drawback of baculovirus vectors has been the inability to transduce cells in animal models in vivo because of complement inactivation. It has also been reported that the VSV-G envelope glycoprotein-pseudotyped lentiviral vectors are sensitive to human complement inactivation, whereas Ampho-pseudotyped vectors are resistant. Gp64 does indeed confer sensitivity to inactivation by human complement, but there was no sensitivity to complement from mice or rats. Since all of the vector pseudotypes (VSV-G, gp64 and Ampho) are produced in the same cell type, the resistance or sensitivity of the vectors is dependent on the identity of the envelope glycoprotein, and not a glycosylation characteristic of the membrane envelope derived from the producer cell. The sensitivity of gp64-and VSV-Gpseudotyped lentiviral vectors to human complement inactivation will be a significant problem for the use of these particles in human gene-transfer protocols that require vascular injections. Fortunately, the problem might be avoided by directly injecting the vectors into specific tissues or through the use of complement regulatory proteins such as DAF (C Schauber, manuscript in preparation).
In rodent serum, we found that gp64-pseudotyped vectors are resistant to complement inactivation. These data are further confirmed by our observation in mouse studies that gp64 efficiently transduces murine cells following injection into the vasculature, contrary to the published reports that baculovirus vectors are sensitive to rodent sera and do not transduce cells in vivo after vascular injection. Therefore, it is likely that baculovirus sensitivity to rodent complement is a result of recognition of elements derived from the insect producer cell membrane or other baculovirus envelope proteins and not specific to the gp64 glycoprotein itself.
In summary, our findings suggest that the gp64 envelope glycoprotein is a useful component of the lentiviral vector system because it confers high transduction efficiency in vitro and in vivo. It has the advantages over the VSV-G envelope that it can be stably expressed without cytotoxic effects, allowing a generation of a packaging cell line without inducible expression. Finally, gp64 can be a useful alternative to VSV-G for many applications because it transduces cells in vivo with a similar efficiency but has a more restricted tropism profile, especially with respect to cells of the hematopoietic system, including DCs.
Materials and methods

Plasmid constructs
The VSV-G and baculovirus (AcNPV) gp64 envelope genes were subcloned into a mammalian expression vector (pMD-2) 23 that carries a CMV promoter, a b-globin intron upstream of the ORF and a b-globin poly A signal. The VSV-G ORF fragment was removed by EcoRI digestion of pMD.G 4 with EcoRI and ligated into EcoRIdigested pMDLg/pRRE 23 to produce pMD2-VSVG-Env (pCG909). The gp64 ORF fragment was prepared by PCR amplification of the AcNPV envelope region from BacPak6 (Clontech, Palo Alto, CA, USA) with addition of EcoRI sites at each end. The primers used for amplification are as follows: forward primer 5 0 -acctgggaattcgccgccaccatgctactagtaaatcagtcacaccaa-3 0 (adds an EcoRI site and a Kozak consensus sequence upstream of the ATG); reverse primer 5 0 -actgacgaattcttaatattgtctattacggtttcta 0 3 0 (adds an EcoRI site downstream of the stop codon). PCR amplification using these primers produced a product of 1.6 kb. The PCR product was digested with EcoRI and ligated into EcoRI cut pMDLg/p.RRE to produce pMD2-AcNPV-Env (pCG917). For both VSV-G and gp64, the resulting plasmids were confirmed by sequencing.
Cell culture
The following cell lines were obtained from ATCC and HuH7 cells were obtained from Dr Jing-Hsuing (James) Ou, at the University of Southern California. HUAEC (#CC-2520) and NHDC (CC-2701) were both obtained from Cambrex (East Rutherford, NJ, USA) and cultured in the specified Clonetics media. Cells were grown at 371C in 5% CO 2 at 85% humidity.
Small-scale production of pseudotyped lentiviral vectors by transient transfection
Third-generation HIV-1 vectors were prepared by transient transfection, according to published procedures, 23 using a mixture of four plasmids in the following amounts per 10 cm dish: pMDLg/pRRE (Gag/Pol expression plasmid) at 6.5 mg, pRSV-Rev 23 Gag concentration were performed as previously described. 23 Large-scale production and purification of pseudotyped lentiviral vectors Large-scale preparations of pseudotyped vectors were produced by transient transfection in 10-stack cell factories (Nunc, Rochester, NY, USA) as follows: lowpassage 293T cells were expanded and seeded at 5.75 Â 10 8 cells per cell factory the day prior to transfection. The following day, the medium on the cells was changed 2 h prior to transfection. Four plasmids were cotransfected in the following amounts per cell factory: pMDLg/p.RRE at 747.5 mg, pRSV-Rev at 287.5 mg, Transfer Vector (pRRL.sin.CMV.eGFP.ppt.pre or pRRL.sin.CM-V.eGFP.pre or pRRL.sin.CMV.hFIX.ppt.pre) 41 at 1.15 mg and 402.5 mg of envelope plasmid (pMD2.VSVG-Env or pMD2.AcNPV.Env or pMD2.Ampho.Env). For each cell factory, the DNA was mixed with 0.1 Â TE to a final volume of 51.75 ml. Next, 5.75 ml of 2.5 M CaCl 2 was added and mixed. This mixture was then added to 57.5 ml of 2 Â HBS and added to the 10-stack. The medium was changed 16 h later and conditioned medium containing vector particles was harvested in two collections at 24 and 48 h after the medium change. Vectors were purified by DEAE ion exchange (ToyoPearl DEAE-650C) chromatography by loading the conditioned medium at a 20:1 ratio of load volume to bed volume. The column was then washed with 5 volumes of PBS and eluted with 2.5 volumes of PBS containing 0.75 M NaCl. The eluate was further concentrated by ultracentrifugation as for small-scale vector preparations. For the human Factor IX vectors that were injected into mice, TU were calculated based on the p24
Gag concentration and the average infectivity (in TU/ng p24 Gag ) determined for GFP vectors with the same pseudotypes.
In vivo mouse studies
All animal work was approved by the Institutional Animal Care and Use Committee at Cell Genesys. Female NIH Swiss Nude, 6-8-week old (Taconic, Germantown, NY, USA), mice were cannulated in the hepatic portal vein 1 to 2 days prior to injection. Vectors were injected into the cannula at a total volume of 100 ml. Blood was collected from the retro-orbital plexus at the indicated time points and processed into serum for human Factor IX analysis. For GFP analysis, animals were euthanized 11 days after injection, and the medial and left lateral lobes of the liver were collected and processed for GFP analysis, as described below.
ELISA determination of human Factor IX concentration
Flat-bottomed 96-well plates (Nunc, Rochester, NY, USA) were coated with 100 ml/well of mouse monoclonal antihuman Factor IX antibody (Roche Applied Science, Indianapolis, IN, USA) diluted to 2 mg/ml in boric acid-buffered saline (BBS) and left overnight at 41C. Following coating, the plates were washed with BBS containing 0.025% Tween-20, and blocked with 200 ml/ well BBM (1% nonfat milk in BBS) for 2 h at room temperature. Standards were made using serial dilutions of 20% naïve mouse serum in BBM spiked with human Factor IX (Calbiochem, La Jolla, CA, USA, 25 ng/ml starting concentration). Mouse serum samples were diluted 1:5 or 1:10 in BBM and 50 ml/well was loaded in duplicate. In 1:10 dilutions, naïve mouse serum was added to the dilution to make a final solution of 20% mouse serum in BBM. After a 2-h incubation at room temperature, the plates were washed and incubated for 90 min with 50 ml/well horseradish peroxidase (HRP)-conjugated goat anti-human Factor IX polyclonal antibody (Affinity Biologicals, Ancaster, ON, Canada) that was diluted 1:100 in BBM. After a final wash step, the plates were developed with 50 ml/well o-phenylenediamine dihydrochloride peroxidase substrate (Sigma, St Louis, MO, USA). After 25 min, the color reaction was stopped by adding 50 ml/well 2 M H 2 SO 4 , and the optical density was determined by reading in a plate reader/ spectrophotometer at 490 nm. The limit of detection for the ELISA is approximately 1 ng/ml.
Liver histology
Livers were processed as previously described for in situ hybridization of mouse embryos. 42 The medial and left lateral lobes of the mouse livers were analyzed separately. Samples were cyrosectioned at 5-10 mm and directly visualized for GFP fluorescence using a Zeiss Axioplan microscope (Carl Zeizz, Thornwood, NY, USA).
Determination of complement sensitivity
Serum samples from single human donors, Nude rats or pooled sera from C57BL/6 mice were thawed and half of each serum sample was heated at 561C for 1 h to inactivate the complement. All sera were made by collecting fresh whole blood and allowing it to clot completely for several hours. Clots were pelleted by centrifugation and the serum supernatants were removed and frozen immediately in aliquots. CMV-GFP vector samples with different envelope pseudotypes were diluted to 10 6 TU/ml. A volume of 30-75 ml of the vector was diluted 1:5 into normal or heat-inactivated serum (or medium containing 10% heat-inactivated FBS as the no-serum control) and the mixture was incubated at 371C for 1 h. Following the incubation, medium was added to the reaction for an additional 1:5 dilution and then serially diluted twice at a 1:10 ratio, and used to infect 293T cells in the presence of 8 mg/ml Polybrene for end-point titer determination. The titer value was divided by the titer determined for the vector mixed with medium (the no-serum control), and reported as the % recovery of titer compared to this control. All serum samples were analyzed for hemolytic complement activity (CH 50 ) using kits from Quidel (CH 50 Eq Enzyme Immunoassay; San Diego, CA, USA) or Diamedix (E-Z CH 50 ; Miami, FL, USA).
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